153 related articles for article (PubMed ID: 19674876)
1. Phospholipidosis in healthy subjects participating in clinical studies: ultrastructural findings in white blood cells.
Pospischil A; Walther P; Dingemanse J
Exp Toxicol Pathol; 2010 Sep; 62(5):567-71. PubMed ID: 19674876
[TBL] [Abstract][Full Text] [Related]
2. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system.
Sawada H; Takami K; Asahi S
Toxicol Sci; 2005 Feb; 83(2):282-92. PubMed ID: 15342952
[TBL] [Abstract][Full Text] [Related]
3. In vitro assays and biomarkers for drug-induced phospholipidosis.
Monteith DK; Morgan RE; Halstead B
Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):687-96. PubMed ID: 17014389
[TBL] [Abstract][Full Text] [Related]
4. Experimental phospholipidosis induced by 4,4'-diethyl-aminoethoxyhexestrol. Morphological and biochemical interpretations.
Tashiro Y; Watanabe Y; Enomoto Y
Acta Pathol Jpn; 1983 Sep; 33(5):929-42. PubMed ID: 6316720
[TBL] [Abstract][Full Text] [Related]
5. Drug-induced phospholipidosis.
Anderson N; Borlak J
FEBS Lett; 2006 Oct; 580(23):5533-40. PubMed ID: 16979167
[TBL] [Abstract][Full Text] [Related]
6. Cell-based fluorescence assay for evaluation of new-drugs potential for phospholipidosis in an early stage of drug development.
Fujimura H; Dekura E; Kurabe M; Shimazu N; Koitabashi M; Toriumi W
Exp Toxicol Pathol; 2007 Aug; 58(6):375-82. PubMed ID: 17408938
[TBL] [Abstract][Full Text] [Related]
7. Cationic amphiphilic drug-induced phospholipidosis.
Halliwell WH
Toxicol Pathol; 1997; 25(1):53-60. PubMed ID: 9061852
[TBL] [Abstract][Full Text] [Related]
8. In vivo and in vitro reversibility of chlorphentermine-induced phospholipidosis in rat alveolar macrophages.
McCloud CM; Beard TL; Kacew S; Reasor MJ
Exp Mol Pathol; 1995 Feb; 62(1):12-21. PubMed ID: 7556587
[TBL] [Abstract][Full Text] [Related]
9. Cellular responses associated with dibucaine-induced phospholipidosis.
Peropadre A; Fernández Freire P; Herrero O; Pérez Martín JM; Hazen MJ
Chem Res Toxicol; 2011 Feb; 24(2):185-92. PubMed ID: 21261262
[TBL] [Abstract][Full Text] [Related]
10. Inhaled cationic amphiphilic drug-induced pulmonary phospholipidosis in rats and dogs: time-course and dose-response of biomarkers of exposure and effect.
Pauluhn J
Toxicology; 2005 Feb; 207(1):59-72. PubMed ID: 15590122
[TBL] [Abstract][Full Text] [Related]
11. Drug-induced phospholipidosis: are there functional consequences?
Reasor MJ; Kacew S
Exp Biol Med (Maywood); 2001 Oct; 226(9):825-30. PubMed ID: 11568304
[TBL] [Abstract][Full Text] [Related]
12. A 96-well flow cytometric screening assay for detecting in vitro phospholipidosis-induction in the drug discovery phase.
Natalie M; Margino S; Erik H; Annelieke P; Geert V; Philippe V
Toxicol In Vitro; 2009 Mar; 23(2):217-26. PubMed ID: 19101623
[TBL] [Abstract][Full Text] [Related]
13. High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis.
van de Water FM; Havinga J; Ravesloot WT; Horbach GJ; Schoonen WG
Toxicol In Vitro; 2011 Dec; 25(8):1870-82. PubMed ID: 21651975
[TBL] [Abstract][Full Text] [Related]
14. X-ray microanalysis of cultured alveolar macrophages with phospholipidosis.
Lee P; Kirk RG; Reasor MJ
Exp Mol Pathol; 1993 Apr; 58(2):96-104. PubMed ID: 8388333
[TBL] [Abstract][Full Text] [Related]
15. Relationship between in vitro phospholipidosis assay using HepG2 cells and 2-week toxicity studies in rats.
Miyamoto S; Matsumoto A; Mori I; Horinouchi A
Toxicol Mech Methods; 2009 Oct; 19(8):477-85. PubMed ID: 19793005
[TBL] [Abstract][Full Text] [Related]
16. Two single-center, double-blind, randomized, placebo-controlled, phase I studies to investigate the tolerability and pharmacokinetics of CH-1504, an antifolate, in healthy male subjects.
Mant T; Jurcevic S; Szakacs C; Adams L; Boland J; Hewitt LA
Clin Ther; 2008 Jan; 30(1):131-42. PubMed ID: 18343249
[TBL] [Abstract][Full Text] [Related]
17. Drug-induced phospholipidosis is caused by blockade of mannose 6-phosphate receptor-mediated targeting of lysosomal enzymes.
Ikeda K; Hirayama M; Hirota Y; Asa E; Seki J; Tanaka Y
Biochem Biophys Res Commun; 2008 Dec; 377(1):268-74. PubMed ID: 18840403
[TBL] [Abstract][Full Text] [Related]
18. Phospholipidosis effect of drugs by adsorption into lipid monolayers.
Ceccarelli M; Germani R; Massari S; Petit C; Nurisso A; Wolfender JL; Goracci L
Colloids Surf B Biointerfaces; 2015 Dec; 136():175-84. PubMed ID: 26387069
[TBL] [Abstract][Full Text] [Related]
19. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
Kisicki JC; Fiske K; Lyne A
Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced phospholipidosis.
Lüllmann H; Lüllmann-Rauch R; Wassermann O
Ger Med; 1973; 3(3-4):128-35. PubMed ID: 4370610
[No Abstract] [Full Text] [Related]
[Next] [New Search]